Available for Sale Debt Securities (Tables)

12 Months Ended

Dec. 31, 2022

Investments, Debt and Equity Securities [Abstract]

Summary of Available for Sale Debt Securities

The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2022 and 2021 (in thousands):


	Cost		Unrealized (Losses)/Gains		Fair Value		Current Assets		Non-Current Assets		Current Liabilities		Non-Current Liabilities		Total
As of December 31, 2022
Debt securities (1)	$	359,400	$	(131,800)	$	227,600	$	1,300	$	226,300	$	—	$	—	$	227,600

Funding commitments (2)	(9,400)		6,900		(2,500)		—				—		(2,500)		(2,500)
Total available for sale debt securities	$	350,000	$	(124,900)	$	225,100	$	1,300	$	226,300	$	—	$	(2,500)	$	225,100

As of December 31, 2021
Debt securities (3)	$	204,509	$	49,191	$	253,700	$	66,000	$	187,700	$	—	$	—	$	253,700
Forwards (4)	—		16,700		16,700		—		16,700		—		—		16,700
Total available for sale debt securities	$	204,509	$	65,891	$	270,400	$	66,000	$	204,400	$	—	$	—	$	270,400

(1)The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. The cost of the Development Funding Bonds represents the amounts funded.

(2)The cost associated with the Cytokinetics Funding Commitments represents the fair value on the purchase date.

(3)The cost for the Series A Biohaven Preferred Shares represents amortized cost. The cost for the Series B Biohaven Preferred Shares represents the

amounts paid to purchase the instruments. These instruments were fully redeemed during 2022.

(4)There are no costs associated with the forwards.